Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study’s final report confirms letrozole’s benefit for breast cancer patients

07.09.2005


Aromatase inhibitor improves survival for some patients, reduces metastasis

The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with tamoxifen. It also finds that letrozole prevents the development of metastases, even in women whose cancer had originally spread to their lymph nodes. The report appears in the September 7 issue of the Journal of the National Cancer Institute.

"The most important new findings we describe in this article are that letrozole treatment can improve the survival of women with node-positive disease and can reduce the chance that metastatic tumors will develop," says Paul E. Goss, MD, PhD, who led the investigation. At the study’s outset, Goss was with the Princess Margaret Hospital in Toronto; he now is director of Breast Cancer Research at Massachusetts General Hospital Cancer Center.



Letrozole is one of a class of drugs called aromatase inhibitors that suppress the production of estrogen. Estogen stimulates the growth of breast tumors that express the estrogen receptor, and drugs that block the production or the action of the hormone are used in the treatment of those tumors. The most widely used estrogen-blocking drug is tamoxifen, which becomes ineffective after five years of treatment, probably because tumor cells become resistant to or even dependent on the drug.

The international study, called the MA.17 trial, was conducted through the National Cancer Institute of Canada and designed to test whether letrozole could reduce tumor recurrence and increase survival in postmenopausal breast cancer patients who had completed five years of tamoxifen treatment. More than 5,000 women were enrolled and randomly assigned to receive either letrozole or a placebo for an additional five years. The study was halted in October 2003 – four years after it began – when an interim data analysis showed that the tumors of women taking letrozole were significantly less likely recur. Those results were published in the November 6, 2003 New England Journal of Medicine.

The current report analyzes all the data compiled during the MA.17 trial and confirms that the risk of recurrence was almost 5 percent lower in those receiving letrozole than in the placebo group. Women receiving the drug also had a 39 percent reduction in the risk of metastasis. While overall survival differences between the two groups were not significant, among women whose tumors had spread to their lymph nodes and those who had received tamoxifen for more than five years, letrozole was associated with significantly better overall survival.

Although participants taking letrozole did have a greater incidence of osteoporosis, there was no significant difference in reported fractures. There was also no increased risk of cardiovascular problems, which Goss says is particularly noteable. "A recent trial comparing letrozole to tamoxifen found that letrozole might be associated with heart problems. But our study, the only placebo-controlled trial of an aromatase inhibitor, found no such association. A possible explanation of the earlier study was that tamoxifen may actually protect against cardiovascular disease, which our results support."

Goss adds that current and future studies will investigate two key questions about letrozole and other aromatase inhibitors – how long treatment should continue and whether the drugs also can benefit women who previously stopped taking tamoxifen or never took that drug. One trial that has already begun will continue following the women who received letrozole throughout the MA.17 trial and re-randomize them to receive either letrozole or a placebo for an additional five years. Another study will examine tumor samples from all MA.17 trial participants to search for molecular fingerprints that might identify who would most benefit from letrozole treatment.

Emily Parker | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Studies and Analyses:

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

nachricht Scientists reveal source of human heartbeat in 3-D
07.08.2017 | University of Manchester

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>